Diabetic gastroparesis: pathophysiology and impact on insulin timing choices
Open accessThe DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index; 140 of the 258 sources its claims cite were checked for support.
Abstract
Diabetic gastroparesis (DGP) is a chronic and frequently underrecognized complication of diabetes mellitus, characterized by delayed gastric emptying in the absence of mechanical obstruction. ... The altered timing and variability of gastric emptying disturb the physiological coordination between nutrient absorption and insulin pharmacokinetics, generating a temporal mismatch that predisposes patients to early postprandial hypoglycemia followed by late hyperglycemia.
Overview
CoChat Summary
## TL;DR
This narrative review explains diabetic gastroparesis as a multifactorial complication of diabetes that disrupts gastric emptying and creates a mismatch between nutrient absorption and insulin action. It argues that insulin timing must be individualized using symptoms, meal characteristics, and CGM data, because delayed and erratic emptying can cause early hypoglycemia and late hyperglycemia.
## Key findings
- Diabetic gastroparesis is estimated to affect 5%–12% of individuals with long-term diabetes when systematic gastric emptying evaluation is used; in one large US cohort based on clinical diagnosis, prevalence was 4.6% in type 1 diabetes and 1.3% in type 2 diabetes.
- In diabetic subjects without gastroparesis, prandial insulin is typically given 10–15 min before a meal; in DGP, delayed and variable emptying causes insulin-nutrient mismatch, with early postprandial hypoglycemia and late postprandial hyperglycemia.
- For refractory disease, the review reports that G-POEM has shown around 70% success at 1 year in small series, while gastric electrical stimulation and laparoscopic pyloromyotomy are also discussed as options for selected patients.
- The review states that CGM, CSII/SAP, and hybrid closed-loop/AID systems can improve glycemic management in DGP, but the evidence remains limited and largely observational.
## Methods
- This is a narrative review, not a systematic review or meta-analysis.
- The authors searched MEDLINE via PubMed up to 14 December 2025, using terms related to diabetic gastroparesis, autonomic/enteric neuropathy, gastric motor dysfunction, and gastric emptying disorders, and also screened reference lists of included articles and prior reviews.
- Studies were selected by relevance and study quality; data were extracted using a PICO framework from text, tables, and figures. No formal risk-of-bias assessment was performed.
## Limitations
- The paper explicitly states that it is a narrative review, with no formal meta-analysis, no systematic review methodology, and no formal risk-of-bias assessment.
- The authors say that robust clinical evidence specifically addressing patients with DGP remains limited, and that prospective validation of some technologies in DGP is still needed.
- Evident from the text: many treatment claims are based on small series, observational data, or selected studies, so conclusions about efficacy are not supported by high-level comparative evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
63 Valid · 7 Not valid · 20 Not checked · 9 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In diabetes, chronic hyperglycemia, and reduced trophic factors, in particular the reduction of KIT/stem cell factor (SCF), cause the loss or dysfunction of ICCs [52], leading to dysregulated gastric emptying [4, 19, 53].”
§ Diabetic gastroparesis: pathophysiology and impact on insulin timing choices > Pathophysiology > “Cajalopathy”: dysfunction of interstitial cells of cajal (ICCs)
What the sources say
- Disputedcites [52] V.J. Horváth, H. Vittal, T. Ördög, Reduced Insulin and IGF-I Signaling, not Hyperglycemia, Underlies the Diabetes-Associated Depletion of Interstitial Cells of Cajal in the Murine Stomach. Diabetes. 54, 1528–1533 (2005). https://doi.org/10.2337/DIABETES.54.5.1528 sourceExperimental — accuracy not yet measured
The Results and Discussion (pp. 3–4) report that long-term hyperglycemia did not damage ICC networks; insulin or IGF-I prevented their depletion. The Discussion (p. 4) mentions stem cell factor only as a possible mediator of insulin’s effects, not as a demonstrated factor reduced in diabetes. The paper therefore contradicts the claim that chronic hyperglycemia causes ICC loss and does not establish the claimed SCF mechanism. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [4] M. Camilleri, Diabetic Gastroparesis. N Engl. J. Med. 356, 820–829 (2007). https://doi.org/10.1056/NEJMCP062614 source
- Partly supportedcites [19] A.E. Bharucha, Y.C. Kudva, D.O. Prichard, Diabetic Gastroparesis. Endocr. Rev. 40, 1318–1352 (2019). https://doi.org/10.1210/ER.2018-00161 sourceExperimental — accuracy not yet measured
The enteric neuromuscular disturbances passage (indexed as Abstract; page unavailable) reports ICC loss in human diabetic gastroparesis and says reduced stem cell factor production may deplete ICCs in murine models. It also says the mechanisms of ICC loss are unclear and describes the link to delayed gastric emptying as a hypothesis. The claim overstates these tentative findings as an established causal chain from chronic hyperglycemia and reduced SCF to ICC loss and dysregulated emptying. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [53] I. Soykan, B. Sivri, I. Sarosiek et al., Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig. Dis. Sci. 43, 2398–2404 (1998). https://doi.org/10.1023/A:1026665728213 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“whereas Domperidone and Erythromycin require careful cardiac monitoring [3, 14, 123].”
§ Diabetic gastroparesis: pathophysiology and impact on insulin timing choices > Clinical impact and management of insulin therapy > Management of insulin therapy
What the sources say
- Disputedcites [3] M. Camilleri, B. Kuo, L. Nguyen et al., ACG Clinical Guideline: Gastroparesis. Am. J. Gastroenterol. 117, 1197 (2022). https://doi.org/10.14309/AJG.0000000000001874 sourceExperimental — accuracy not yet measured
The guideline’s motilin-agonists discussion (page unavailable) says macrolide use, which includes erythromycin, was not associated with arrhythmia or cardiovascular mortality. Its domperidone trial summary (page unavailable) reports no significant cardiovascular complications in one cohort. Rather than recommending careful cardiac monitoring for either drug, the cited passages make contrary cardiac-safety points. (LLM, conf=0.76)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [14] K. Staller, H.P. Parkman, K.B. Greer et al., AGA Clinical Practice Guideline on Management of Gastroparesis. Gastroenterology. 169, 828–861 (2025). https://doi.org/10.1053/J.GASTRO.2025.08.004/ATTACHMENT/F1152A5A-1B30-4C2F-8DEE-598E8130010E/MMC2.PDF doi:10.1053/j.gastro.2025.08.004/attachment/f1152a5a-1b30-4c2f-8dee-598e8130010e/mmc2.pdf
- Not checked — no full text of the sourcecites [123] S.C. Reddymasu, I. Soykan, R.W. McCallum, Domperidone: review of pharmacology and clinical applications in gastroenterology. Am. J. Gastroenterol. 102, 2036–2045 (2007). https://doi.org/10.1111/J.1572-0241.2007.01255.X source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“This condition, often referred to as “cajalopathy”, is considered the most common alteration found in both diabetic and idiopathic gastroparesis [54].”
§ Diabetic gastroparesis: pathophysiology and impact on insulin timing choices > Pathophysiology > “Cajalopathy”: dysfunction of interstitial cells of cajal (ICCs)
What the sources say
- Supportedcites [54] S. Krishnasamy, T.L. Abell, (2018) Diabetic Gastroparesis: Principles and Current Trends in Management. Diabetes Therapy 2018 9:1 9:1–42. https://doi.org/10.1007/S13300-018-0454-9 source
The Pathogenesis section identifies loss of interstitial cells of Cajal (ICC) as “cajalopathy.” The Mechanisms of Diabetic Gastroparesis subsection states that loss of ICC is the most common enteric abnormality in both diabetic and idiopathic gastroparesis (page not available). (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These cells act as gastrointestinal pacemakers, coordinating the rhythmic contractions necessary for the transit of gastric contents [50, 51].”
§ Diabetic gastroparesis: pathophysiology and impact on insulin timing choices > Pathophysiology > “Cajalopathy”: dysfunction of interstitial cells of cajal (ICCs)
What the sources say
- Supportedcites [50] D. Foong, J. Zhou, A. Zarrouk et al., Understanding the Biology of Human Interstitial Cells of Cajal in Gastrointestinal Motility. Int. J. Mol. Sci. 21, 1–18 (2020). https://doi.org/10.3390/IJMS21124540 source
The Introduction describes ICC as specialised GI pacemaker cells and explains that coordinated waves of contraction move contents through the GI tract. The ICC Subtypes section specifically links stomach ICC to the generation and propagation of slow-wave activity in muscle. The supplied passages do not give page numbers. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [51] J.D. Huizinga, A. Hussain, J.H. Chen, Interstitial cells of Cajal and human colon motility in health and disease. Am. J. Physiol. Gastrointest. Liver Physiol. 321, G552–G575 (2021). https://doi.org/10.1152/AJPGI.00264.2021 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Importantly, these myogenic changes may occur in parallel with neuronal injury, supporting the concept of a partly independent muscular pathway in the disease process [42].”
§ Diabetic gastroparesis: pathophysiology and impact on insulin timing choices > Pathophysiology > Autonomic and enteric neuropathy
What the sources say
- Partly supportedcites [42] M. Camilleri, K.M. Sanders, Gastroparesis Gastroenterol. 162, 68–87e1 (2022). https://doi.org/10.1053/J.GASTRO.2021.10.028 sourceExperimental — accuracy not yet measured
The Pathophysiology section (Pyloric Dysfunction; page not available) reports changes around smooth muscle cells and abnormalities of neurons or nerve endings in gastroparesis. It also suggests that pyloric dysfunction could reflect ICC damage rather than neuropathy. These passages support a possible non-neuronal contribution, but do not establish that myogenic changes occur in parallel with neuronal injury or identify a partly independent muscular pathway. (LLM, conf=0.78)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 26 with their cited sources checked
Create a free account to see all 99 claims and to verify the 23 references still open.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 51
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Utilization of the PICO framework to improve searching PubMed for clinical questions
Schardt, C., Adams, M. B., Owens, T., Keitz, S., & Fontelo, P. (2007) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-7-16 · Cited by 3,053 · cited 1×
“All data were extracted from articles’ text, tables, and figures using the Population, Intervention, Comparison, and Outcome (PICO) framework [26] and included at least the following: title, authors, year of publication, study design, study population, outcomes, and main results.”
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 3×
“CGM helps characterize the timing, amplitude, and frequency of excursions [133–139], and provides quantitative metrics such as TIR, time in hypoglycemia (TBR) and hyperglycemia (TAR), and indices of glycemic variability, which are increasingly used as clinically meaningful targets in diabetes…”
Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1553 · Cited by 2,044
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915 · cited 1×
“Excess intracellular glucose promotes mitochondrial over-activity, leading to an increased formation of reactive oxygen and nitrogen species (ROS, RNS) [32].”
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831 · cited 1×
“…the timing, amplitude, and frequency of excursions [133–139], and provides quantitative metrics such as TIR, time in hypoglycemia (TBR) and hyperglycemia (TAR), and indices of glycemic variability, which are increasingly used as clinically meaningful targets in diabetes management [140–144].”
Parkman, H. P., Hasler, W. L., & Fisher, R. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.055 · Cited by 738
DiMeglio, L. A., Acerini, C. L., Codner, E., Craig, M. E., Hofer, S. E., Pillay, K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12737 · Cited by 604 · cited 1×
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588 · cited 1×
“It also complicates both the achievement of recommended glycated hemoglobin (HbA1c) and time in range (TIR) targets [101, 102].”
Soykan, I., Sivri, B., Sarosiek, I., Kiernan, B., & Mccallum, R. W. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1026665728213 · Cited by 575 · cited 1×
“In diabetes, chronic hyperglycemia, and reduced trophic factors, in particular the reduction of KIT/stem cell factor (SCF), cause the loss or dysfunction of ICCs [52], leading to dysregulated gastric emptying [4, 19, 53].”
Research works printed but not linked: 1
- S. Krishnasamy, T.L. Abell, Diabetic Gastroparesis: Principles and Current Trends in Management. Diabetes Therapy. 9, 1 (2018). https://doi.org/10.1007/S13300-018-0454-9 · DOI · Paper page
Metadata
- Authors
- Galeano, F., Tumminia, A., Oteri, V., Le Moli, R., Piticchio, T., Scilletta, S., Di Marco, M., Di Pino, A., & Frasca, F.
- Affiliations
- University of Catania (IT)
- Ospedale Garibaldi (IT)
- Ospedale Cannizzaro (IT)
- Corresponding author
- Galeano, Francesco
- ORCID
- Venue
- Endocrine
- Published
- 2026-06-23
- Volume
- 91
- Issue
- 1
- ISSN
- 0969-711X (ISSN-L)
- 1559-0100
- PMC
- PMC13290835
- OpenAlex
- W7165660797
- Cited by
- 0
- References
- 179
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Endocrine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Università degli Studi di Catania
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic gastroparesis, delayed gastric emptying, diabetic autonomic neuropathy, postprandial hypoglycemia, glycemic variability, oxidative stress, advanced glycation end products, IGF-1 signaling, interstitial cells of Cajal, continuous glucose monitoring, artificial pancreas, glucose-responsive insulin, diabetes complications
- MeSH terms
- Animals, Diabetic Neuropathies, Gastric Emptying, Humans, Hypoglycemic Agents, Insulin, Gastroparesis, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetic gastroparesis: pathophysiology and impact on insulin timing choices. https://app.cochat.ai/papers/10.1007/s12020-026-04693-6
- The paper
- Galeano, F., Tumminia, A., Oteri, V., Le Moli, R., Piticchio, T., Scilletta, S., Di Marco, M., Di Pino, A., & Frasca, F. (2026). Diabetic gastroparesis: pathophysiology and impact on insulin timing choices. Endocrine. https://doi.org/10.1007/s12020-026-04693-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

